Ligand Pharmaceuticals Inc. (LGND) Earns $1 Million Milestone Payment Triggered By FDA Approval Of FDA's NOXAFIL® (Posaconazole) Injection For Intravenous Use, A New Captisol-Enabled Formulation
3/17/2014 9:16:48 AM
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration (FDA) approval of Merck’s NOXAFIL® (posaconazole) injection (18 mg/mL). This is a new Captisol®-enabled formulation of NOXAFIL for intravenous (IV) use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
Help employers find you! Check out all the jobs and post your resume
comments powered by